```html
What is the CJC-1295 + Ipamorelin stack? It is a two-peptide research combination containing CJC-1295 and ipamorelin. The name describes a combination rather than a universally standardized pharmaceutical formulation. Commonly encountered research-vendor configurations include a 5 mg CJC-1295 + 5 mg ipamorelin blend, while regulatory records have also documented compounded products with different component ratios. Most importantly, evidence for either peptide individually should not be interpreted as clinical evidence that the combined product is effective or safe.
CJC-1295 + Ipamorelin is a two-component peptide research blend. CJC-1295 is a synthetic GHRH-related peptide, while ipamorelin is a growth-hormone secretagogue associated with the ghrelin receptor pathway. The two are frequently discussed or sold together, but the combination itself is not a standardized, FDA-approved pharmaceutical formulation.
FDA documentation has specifically noted that CJC-1295 records may involve different forms, including CJC-1295 free base, acetate, and DAC-associated forms. This is one reason a BacScience research page should identify the exact material and formulation rather than treating every product labelled “CJC-1295” as identical.
The blend contains two distinct peptide components. The mathematical concentration of each component depends on its own mass in the vial and the final liquid volume.
CJC-1295 is a modified peptide related to growth-hormone-releasing hormone signalling. Published human work has primarily examined a long-acting DAC-associated form and measured pharmacokinetic and hormonal endpoints.
Research distinction: Always identify whether the material is specified as DAC or without DAC / Mod GRF 1-29.
Ipamorelin is a synthetic peptide associated with growth-hormone secretagogue activity through the GHS-R1a/ghrelin receptor pathway. Human research has included pharmacokinetic/pharmacodynamic work and a clinical investigation in postoperative ileus.
Research distinction: Component-level findings should not be presented as evidence for the CJC-1295 + ipamorelin combination.
No. The name does not establish one universal ratio or one universal CJC-1295 variant. A frequently encountered research-vendor format is 5 mg CJC-1295 + 5 mg ipamorelin, giving 10 mg total peptide. However, FDA documentation also describes a compounded multiple-ingredient product containing 6 mg/mL CJC-1295 and 15 mg/mL ipamorelin, demonstrating that the ratio can differ substantially between preparations.
| Configuration | CJC-1295 | Ipamorelin | Interpretation |
|---|---|---|---|
| Commonly encountered research blend | 5 mg | 5 mg | 1:1 mass ratio; 10 mg total |
| Documented FDA compounding example | 6 mg/mL | 15 mg/mL | 2:5 concentration ratio in that preparation |
| Other marketed configurations | Variable | Variable | Verify the specific label/COA |
The commonly stated rationale is mechanistic rather than clinical: the two compounds are associated with different receptor systems that converge on growth-hormone signalling. That pharmacological rationale can explain why the pair appears in research and market practice, but it does not demonstrate that the specific blend improves a clinical outcome.
CJC-1295 is designed around GHRH-related signalling. The human DAC-associated research literature reported sustained changes in circulating GH and IGF-I following administration of the studied analogue.
Individual-component evidenceIpamorelin acts through the ghrelin/GHS-R1a receptor system and has been investigated for GH-related pharmacology as well as a postoperative gastrointestinal indication.
Individual-component evidenceThe strongest human evidence for CJC-1295 comes from small studies of the long-acting DAC-associated analogue, not from a validated CJC-1295 + ipamorelin blend. In a randomized placebo-controlled study of healthy adults, CJC-1295 produced dose-dependent increases in circulating GH and IGF-I, with the studied long-acting analogue showing a prolonged pharmacokinetic profile.
Teichman and colleagues evaluated CJC-1295 in healthy adults using randomized, placebo-controlled ascending-dose studies. The research focused on hormonal and pharmacokinetic endpoints rather than clinical outcomes such as muscle gain, recovery, or longevity.
The published human work is not evidence that every material marketed as “CJC-1295,” particularly material described as no-DAC/Mod GRF 1-29, has the same pharmacokinetics or clinical evidence.
Ipamorelin has human pharmacokinetic/pharmacodynamic research, but the clinical evidence is limited and does not establish the CJC-1295 + ipamorelin combination. A human volunteer study characterized ipamorelin exposure and GH response. A later randomized clinical study investigated ipamorelin in postoperative ileus rather than as a general-purpose body-composition or performance intervention.
Pharmacokinetic/pharmacodynamic modelling in healthy male volunteers found dose-proportional pharmacokinetics and a transient GH response.
A randomized Phase II study investigated ipamorelin in patients after bowel resection. Its clinical endpoint was gastrointestinal recovery, not validation of the CJC-1295 + ipamorelin stack.
No controlled human clinical trial of the specific CJC-1295 + ipamorelin combination was identified in the sources reviewed for this page. This means the combination should not be described as clinically validated for efficacy, safety, body composition, recovery, performance, or longevity.
For a multi-component vial, calculate each peptide independently: concentration = component mass ÷ final liquid volume. Do not add the masses together and then use the total as the concentration of each peptide.
| Liquid volume | CJC-1295 | Ipamorelin | Total peptide concentration | CJC : Ipamorelin |
|---|---|---|---|---|
| 1 mL | 5 mg/mL | 5 mg/mL | 10 mg/mL | 1 : 1 |
| 2 mL | 2.5 mg/mL | 2.5 mg/mL | 5 mg/mL | 1 : 1 |
| 3 mL | 1.667 mg/mL | 1.667 mg/mL | 3.333 mg/mL | 1 : 1 |
| 4 mL | 1.25 mg/mL | 1.25 mg/mL | 2.5 mg/mL | 1 : 1 |
| 5 mL | 1 mg/mL | 1 mg/mL | 2 mg/mL | 1 : 1 |
CJC-1295: 5 mg ÷ 2 mL = 2.5 mg/mL
Ipamorelin: 5 mg ÷ 2 mL = 2.5 mg/mL
The total peptide concentration is 5 mg/mL, but each individual peptide concentration is 2.5 mg/mL.
CJC-1295: 5 mg ÷ 5 mL = 1 mg/mL
Ipamorelin: 5 mg ÷ 5 mL = 1 mg/mL
Increasing the liquid volume fivefold lowers each component concentration fivefold while leaving the amount of peptide in the vial unchanged.
Use the actual mass of each component separately. For example, if a documented vial contained 6 mg CJC-1295 and 15 mg ipamorelin, those two quantities would produce different concentrations at the same final volume. FDA documentation has described a compounded preparation in precisely this type of unequal concentration format.
The ratio between the components is determined by their original masses. Changing the liquid volume changes both concentrations proportionally, but it does not change the underlying mass ratio.
Use the BacScience Universal BAC Water Calculator for single-compound concentration mathematics. For multi-component blends, enter and calculate each ingredient separately rather than treating the blend's total mass as one compound.
Open the BacScience BAC Water CalculatorHuman pharmacodynamic research exists, particularly for the long-acting DAC-associated form. Evidence is limited and does not establish clinical efficacy for the marketed uses commonly associated with peptide stacks.
Human PK/PD research exists, with additional clinical investigation in postoperative ileus. These studies do not validate the CJC-1295 + ipamorelin combination.
No controlled human combination trial was identified in the reviewed literature. Therefore combination efficacy and combination-specific safety remain unestablished.
CJC-1295 + ipamorelin is not an FDA-approved combination product. FDA materials have discussed CJC-1295 and ipamorelin in the context of compounding and safety evaluation, including concerns about peptide characterization, impurities and limited clinical information.
These regulatory observations are not evidence that every research material will produce the same outcome, but they are important reasons to avoid presenting an unapproved peptide blend as though it were a validated pharmaceutical therapy.
Research-use information only. This page is not medical advice and does not recommend administration, dosing, treatment, or use of these compounds in humans or animals.
The most important limitation is the absence of a controlled human trial evaluating the named combination itself.
DAC and no-DAC terminology matters. Results from one molecular configuration should not automatically be transferred to another.
Marketed and compounded formulations may use different component ratios. A vial labelled “10 mg blend” is insufficient to determine the individual concentrations without the per-component specification.
Human studies of the individual compounds have generally focused on pharmacology, hormone concentrations, pharmacokinetics, or specific clinical research questions—not proof of broad performance, recovery, anti-aging, or body-composition claims.
It is a two-peptide combination containing CJC-1295 and ipamorelin. It is commonly encountered as a research blend, but the name does not establish a universally standardized formulation.
No controlled human clinical trial of the specific combination was identified in the reviewed evidence. Individual studies of the two components cannot be treated as combination evidence.
A commonly encountered research configuration is 5 mg CJC-1295 plus 5 mg ipamorelin, for 10 mg total peptide. However, this is not a universal standard. Regulatory records also document other ratios and concentrations.
No. “10 mg blend” can refer to total peptide mass. The actual CJC-1295 and ipamorelin quantities must be read from the formulation label or certificate of analysis.
Divide 5 mg of CJC-1295 by the final liquid volume to obtain CJC-1295 concentration. Separately divide 5 mg of ipamorelin by the same final liquid volume to obtain ipamorelin concentration.
No. In the simple concentration model, changing the liquid volume changes concentration but does not change the mass of peptide originally present.
They should not be treated as interchangeable research materials. The DAC-associated form has substantially different pharmacokinetic characteristics, and the principal published human CJC-1295 study used the long-acting DAC-associated analogue.
No. Combination efficacy and safety require combination-specific research. Separate component evidence can provide mechanistic context but cannot substitute for a controlled study of the pair.
No FDA-approved combination product containing CJC-1295 and ipamorelin has been established by the evidence reviewed for this page.
The BacScience Universal BAC Water Calculator is available at BacScience BAC Water Calculator . For multi-component blends, calculate every ingredient separately.
Link from the concentration section and FAQ.
https://bacscience.com/pages/bac-water-calculatorLink to BacScience's educational article explaining bacteriostatic water, sterile handling concepts, and concentration mathematics.
Link separately to dedicated CJC-1295 and ipamorelin research pages. Keep component evidence separate from the combination page.
```